Showing 2691-2700 of 3223 results for "".
- Zubisoft Launches New IOL Treatment Plannerhttps://modernod.com/news/zubisoft-launches-new-iol-treatment-planner/2479307/Switzerland-based Zubisoft and IBRA have released a new IOL treatment planner, which is now a part of IBRA Cataract Services. In addition to higher visual acuity, the new planner allows surgeons to achieve more accurate results. The lower rate of necessary retreatments results in cost savings for
- US Looks to Spur Advances in COVID-19 Antivirals With $3.2-Billion Infusionhttps://modernod.com/news/us-looks-to-spur-advances-in-covid-19-antivirals-with-3-2-billion-infusion/2479304/The US Department of Health and Human Services (HHS) said Thursday that it is allocating $3.2 billion toward the discovery, development and manufacturing of antivirals as part of its strategy to support the next-generation of COVID-19 treatments, according to a FirstWord report. “New antivi
- Market Scope: Ophthalmic Laser Market Expected to Total $376.4 Million in 2021https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-376-4-million-in-2021/2479296/Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total over $376.4 million in 2021 and grow at a compound annual rate of 2.4 percent from 2021 to 2026, according to Market Scope estimates. Factor
- J&J Vision Launches Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System in Europehttps://modernod.com/news/jj-vision-announces-launch-of-tecnis-eyhance-toric-ii-iol-with-tecnis-simplicity-delivery-system-in-europe/2479274/Johnson & Johnson Vision announced the launch and availability of its Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System for the treatment of cataracts patients with astigmatism in Europe. This monofocal lens allows for high-quality vision at both intermediate and far distance
- Ocuphire Announces Appointment of Jay S. Pepose, MD, PhD, to Its Board of Directorshttps://modernod.com/news/ocuphire-announces-appointment-of-jay-s-pepose-md-phd-to-its-board-of-directors/2479272/Ocuphire Pharma announced the appointment of Jay S. Pepose, MD, PhD, to its Board of Directors. Concurrent to Dr. Pepose’s appointment at Ocuphire’s annual shareholder meeting on June 7, Alan Meyer, MBA, retired from his role on the Board of Directors, having served since April 2018. “We a
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- Lighthouse Guild Starts Construction on New Technology Centerhttps://modernod.com/news/lighthouse-guild-starts-construction-on-new-technology-center/2479265/Lighthouse Guild has started construction on a Technology Center that will be the largest, premier assistive technology resource in the United States, according to a news release. Designed for people who are visually impaired and for all people who are using technology in order to help them, it i
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro
- CooperVision Expands Leadership Teamhttps://modernod.com/news/coopervision-expands-leadership-team/2479259/CooperVision announced the hiring of Kamela Bearlin as Senior Global Brand Director, 1 Day Brands; and Jennifer Lambert as Senior Global Brand Director, Myopia Management; and promoted Elizabeth Lumb, BSc(Hons) MCOptom, FBCLA, to Director of Global Professional Affairs, Myopia Management.
- Avellino Launches AvaGen as First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophieshttps://modernod.com/news/avellino-launches-avagen-as-first-genetic-test-to-quantify-keratoconus-risk-and-presence-of-corneal-dystrophies/2479255/Avellino Lab USA announced full nationwide availability in the US of AvaGen, as the first genetic test that helps determine a patient’s risk of keratoconus and the presence of other corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions